// App-Quantinova.ai

1419 : DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Researchers

Presenter

  • Rakesh Popat

Principal Investigators

  • Keith Stockerl-Goldstein

  • Rafat Abonour

  • Ryan Ramaekers

  • Amit Khot

  • Adam Forbes

  • Cindy Lee

  • Bradley Augustson

  • Andrew Spencer

  • Maria-Victoria Mateos

  • Bikramjit Chopra

  • Rachel Rogers

  • Deborah A Smith

  • Jacqueline Davidge

  • Rocio Montes de Oca

  • Geraldine Ferron-Brady

  • Anne Yeakey

  • Mala Talekar

  • Brandon E. Kremer

  • Ira Gupta

  • Hang Quach

Medical Centers

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Saint Louis University Medical School, St. Louis, MO

  • Queen Elizabeth Hospital, Adelaide, Australia

  • Saint Francis Cancer Treatment Center, Grand Island, NE

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Royal Cornwall Hospital, Truro, United Kingdom

  • Department of Haematology, Royal Adelaide Hospital & The Queen Elizabeth Hospital, Adelaide, SA, Australia

  • Department of Clinical Haematology,Sir Charles Gairdner Hospital,Nedlands,Australia

  • Department of Clinical Haematology, The Alfred Hospital and Monash University, Melbourne, Australia

  • Cancer Research Center-IBMCC (USAL-CSIC), University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain

  • GlaxoSmithKline, Uxbridge, United Kingdom

  • GlaxoSmithKline, Upper Providence, PA

  • GlaxoSmithKline, Waltham, MA

  • University of Melbourne, St. Vincent's Hospital Melbourne,Melbourne, VIC,Australie

Locations

  • United Kingdom

  • United States

  • Australia

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • GSK2857916

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Bortezomib

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • II

Study Id's

  • NCT03525678

  • NCT03544281

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved